協會簡介
1
衛教資訊
2
藥物測試研究
3
NF國際醫療測試研究 - 54
http://www.nf.org.tw/custom_32020.html NF國際醫療測試研究 - 5 NF國際醫療測試研究 - 5 症狀 醫療測試方法  測試期別 CNS Cancer, Meningioma, Hemangioblastoma Drug: Sunitinib  Phase 2 Intracranial Hemangiopericytoma, Neurofibromatosis  Cutaneous Neurofibromas  Procedure: Erbium-YAG laser vaporization  Phase 2 Phase 3 Malignant Peripheral Nerve Sheath Tumors Drug: everolimus Phase 2 Sarcoma  Drug: bevacizumab  neurofibromatosis1 (NF1) Drug: Sorafenib (Nexavar) Phase 2 Recurrent or Progressive Optic Pathway Gliomas (OPG) Recurrent or Progressive Low-grade Glioma  Acoustic Schwannoma, NF1 and NF2  Biological: bevacizumab  Phase 2 Glioma Other: Laboratory Biomarker Analysis Phase 1 Neurofibromatosis Type 1 Other: Pharmacological Study Phase 2 Recurrent Childhood Pilocytic Astrocytoma Drug: Selumetinib  　 Recurrent Childhood Visual Pathway Glioma  　 　 Neurofibromatosis Type 1 Drug: Lenalidomide Phase 2 Recurrent Childhood Pilocytic Astrocytoma Other: Pharmacological Study Recurrent Childhood Visual Pathway Glioma 　 Neurofibromatosis Type 2, Vestibular Schwannomas Drug: RAD001 Phase 0 Meningiomas Vestibular Schwannoma, NF2  Drug: lapatinib  Phase 0 Vestibular Schwannoma, Meningioma, NF 2  Drug: AR-42 (HDAC inhibitor)  Phase 0 Low-Grade Gliomas, Malignant Neoplasms, Brain Drug: MEK162  Phase 1 Soft Tissue Neoplasms  Phase 2 Malignant Peripheral Nerve Sheath Tumors (MPNST) Drug: ganetespib Phase 1 Sarcoma  Drug: Sirolimus  Phase 2 Plexiform Neurofibroma  Drug: PEG-Intron  Phase 2 Solid Tumor and Hematologic Malignancies  Drug: MEK162  Phase 2 在本網頁提供的資料僅供參考，並非對醫療上的建議，也不構成上市臨床活動的認可。以上是美國和歐洲的資訊來源所整理的醫療試驗。 李銘仁整理 2015-12-07  
http://www.nf.org.tw/ 社團法人台灣神經纖維瘤協會
衛教資訊
others

如果您願意幫助神經纖維瘤病友，請支援本會【病友關懷及服務】公益勸募活動(衛部救字第1121363382號)。
協會簡介 衛教資訊 藥物測試研究 NF國際醫療測試研究 - 5

症狀 醫療測試方法  測試期別
CNS Cancer, Meningioma, Hemangioblastoma Drug: Sunitinib  Phase 2
Intracranial Hemangiopericytoma, Neurofibromatosis 
Cutaneous Neurofibromas  Procedure: Erbium-YAG laser vaporization  Phase 2
Phase 3
Malignant Peripheral Nerve Sheath Tumors Drug: everolimus Phase 2
Sarcoma  Drug: bevacizumab 
neurofibromatosis1 (NF1) Drug: Sorafenib (Nexavar) Phase 2
Recurrent or Progressive Optic Pathway Gliomas (OPG)
Recurrent or Progressive Low-grade Glioma 
Acoustic Schwannoma, NF1 and NF2  Biological: bevacizumab  Phase 2
Glioma Other: Laboratory Biomarker Analysis Phase 1
Neurofibromatosis Type 1 Other: Pharmacological Study Phase 2
Recurrent Childhood Pilocytic Astrocytoma Drug: Selumetinib  　
Recurrent Childhood Visual Pathway Glioma  　 　
Neurofibromatosis Type 1 Drug: Lenalidomide Phase 2
Recurrent Childhood Pilocytic Astrocytoma Other: Pharmacological Study
Recurrent Childhood Visual Pathway Glioma 　
Neurofibromatosis Type 2, Vestibular Schwannomas Drug: RAD001 Phase 0
Meningiomas
Vestibular Schwannoma, NF2  Drug: lapatinib  Phase 0
Vestibular Schwannoma, Meningioma, NF 2  Drug: AR-42 (HDAC inhibitor)  Phase 0
Low-Grade Gliomas, Malignant Neoplasms, Brain Drug: MEK162  Phase 1
Soft Tissue Neoplasms  Phase 2
Malignant Peripheral Nerve Sheath Tumors (MPNST) Drug: ganetespib Phase 1
Sarcoma  Drug: Sirolimus  Phase 2
Plexiform Neurofibroma  Drug: PEG-Intron  Phase 2
Solid Tumor and Hematologic Malignancies  Drug: MEK162  Phase 2

在本網頁提供的資料僅供參考，並非對醫療上的建議，也不構成上市臨床活動的認可。以上是美國和歐洲的資訊來源所整理的醫療試驗。

李銘仁整理 2015-12-07

 

上一個 回列表